Fred Jacobs is a Founder and CEO of both Astrimmune and TYG oncology. Fred started his career with PwC in their Washington DC office and was subsequently transferred to their Honolulu office. Fred later become CFO for a biotechnology company and took them through their NASDAQ IPO and subsequent fund raises to support developing treatments for gastrointestinal cancers. Since then, Fred moved to the UK and founded Astrimmune to identify cancer tumours earlier and monitor known cancer patients less invasively and more accurately. Fred also co-founded TYG oncology to treat gastrointestinal cancers, a project supported by CR-UK through first-in-human trials.